- Home
- CLDX
as 11-15-2024 4:00pm EST
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | HAMPTON |
| Market Cap: | 2.9B | IPO Year: | 2008 |
| Target Price: | $64.83 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.49 - $53.18 | Next Earning Date: | 11-06-2024 |
| Revenue: | $9,976,000 | Revenue Growth: | 128.55% |
| Revenue Growth (this year): | -18.63% | Revenue Growth (next year): | -33.62% |
Stock Insider Trading Activity of Celldex Therapeutics Inc. (CLDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Marucci Anthony S | CLDX | PRESIDENT & CEO | Nov 11 '24 | Buy | $26.82 | 11,500 | $308,430.00 | 40,284 |
Latest Celldex Therapeutics Inc. News
CLDX Breaking Stock News: Dive into CLDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Celldex Therapeutics to Present at Upcoming Investor Conferences
Simply Wall St.
9 days ago
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
11 days ago
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
11 days ago
Celldex: Q3 Earnings Snapshot
GlobeNewswire
11 days ago
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
TipRanks
19 days ago
Celldex selloff creates buying opportunity, says Guggenheim
Simply Wall St.
20 days ago
Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years
GlobeNewswire
22 days ago
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
Compare CLDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLDX Celldex Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.